A phase II trial of SVN53-67/M57-KLH (SurVaxM) and TMZ is currently recruiting patients with malignant glioma and the therapy has shown to be well tolerated and generates anti-survivin antibody and survivin specific CD8+ T cells (248). The gene discussed is BIRC5; the disease is malignant glioma.